CellaVision AB

Chart & Performance

D1W1MN

P/E

40.45

P/S

7.78

EPS

5.46

Div Yield, %

1.02%

Shrs. gr., 5y

—

Rev. gr., 5y

13.17%

Revenues

677m

+5.94%

Net income

130m

+10.12%

CFO

196m

+43.09%

Dividend

May 06, 20242.25 SEK/sh

Earnings

Feb 06, 2025

Profile

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

URL

https://www.cellavision.com/

IPO date

May 28, 2007

Employees

235

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	677,292 5.94%	639,340 13.05%	565,552 19.96%
Cost of revenue	510,240	481,074	402,821
Unusual Expense (Income)
NOPBT	167,052	158,266	162,731
NOPBT Margin	24.66%	24.75%	28.77%
Operating Taxes	33,913	30,094	32,958
Tax Rate	20.30%	19.01%	20.25%
NOPAT	133,139	128,172	129,773
Net income	130,309 10.12%	118,335 -5.59%	125,339 40.07%
Dividends	(53,666)	(47,703)	(17,889)
Dividend yield	1.06%	0.87%	0.23%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	36,039	42,131	40,809
Long-term debt	59,611	98,249	131,480
Deferred revenue
Other long-term liabilities	4,945	3,739	3,636
Net debt	(30,391)	26,987	19,996
Cash flow
Cash from operating activities	196,436	137,285	159,717
CAPEX	(31,769)	(69,434)	(84,306)
Cash from investing activities	(85,532)	(70,014)	(84,339)
Cash from financing activities	(97,036)	(90,410)	(48,475)
FCF	134,318	61,076	93,666
Balance
Cash	121,645	108,053	130,286
Long term investments	4,396	5,340	22,007
Excess cash	92,176	81,426	124,015
Stockholders' equity	705,589	630,828	540,863
Invested Capital	693,861	666,378	557,350
ROIC	19.58%	20.95%	25.26%
ROCE	19.76%	19.77%	22.31%
EV
Common stock shares outstanding	23,852	23,852	23,852
Price	212.00 -7.42%	229.00 -29.58%	325.20 5.93%
Market cap	5,056,624 -7.42%	5,462,108 -29.58%	7,756,671 5.93%
EV	5,026,233	5,489,095	7,785,050
EBITDA	206,815	198,363	196,168
EV/EBITDA	24.30	27.67	39.69
Interest	3,260	2,340	1,866
Interest/NOPBT	1.95%	1.48%	1.15%